If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuantum Data Regulatory News (MAST)

  • There is currently no data for MAST

Revenues Update

31 Jul 2025 07:00

RNS Number : 2790T
Mast Energy Developments PLC
31 July 2025
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BNG90H86

('MED' or 'the Company')

 

Dated: 31 July 2025

 

Mast Energy Developments PLC

 

Revenues Update

and Appointment of Investor Relations Firm

 

Mast Energy Developments PLC ("MED" or the "Company") is pleased to announce an update regarding its wholly owned Pyebridge flexible generation power station including latest revenues generated for the first half of 2025, as well as the appointment of a strategic investor relations firm, the highlights and details of which are outlined below.

 

Pyebridge Update:

· MED's 100% owned Pyebridge asset generated and sold c. 4.09 Gigawatt/hours ("GWh") of electricity during the first 6-months of 2025, an increase of c. 0.93 GWh or c. 30% compared to the preceding 6-month period;

· Pyebridge generated and sold c. 7.3 GWh of electricity during the 12-month period ending June 2025;

· Total revenues generated for the first 6-months of 2025 came to c. £746,000, an increase of c. 30% compared to the preceding 6-month period;

· Total revenues based on an average of 5.4 MW in production, representing c. £23k per MW per month;

· Pyebridge average actual electricity sales price achieved during first 6-months of 2025 equates to c. £157 MWh, representing a c. 76% outperformance compared to the average wholesale market electricity price over the same period;

· Pyebridge project finance debt facility with RiverFort total historic draws equals c. £2.77m, of which c. £870k or c. 31% has been repaid over the past 12 months from cash generated by Pyebridge (including VAT refunds); and

· MED management is planning to apply for a final T-4 Capacity Market ("CM") contract for Pyebridge in the upcoming CM prequalification window, with the intention of obtaining a maximum 15-year term CM contract, to supplement Pyebridge's existing CM contracts which cover the periods up to 2029, meaning if the final contract is obtained Pyebridge will have uninterrupted guaranteed CM gross income payments until 2044.

 

Pieter Krügel, MED CEO, commented"We are very proud of the ongoing and increasing positive results from our Pyebridge asset. It is clear that the refurbishment programme launched on the site earlier in 2024 was a success. The ongoing positive results from Pyebridge provides a solid foundation and a clear indication of what we can expect from our further sites that will go into production and revenue generation going forward.

 

With the acquisition of the exclusive rights to a portfolio of development sites as recently announced, effectively doubling MED's portfolio of sites to c. 48 MW once developed, and scalable to 100 MW in the near term, we are making tremendous progress toward our goal of building a portfolio of 300+ MW.

 

We are looking forward to providing the market with further positive updates over the coming weeks."

 

Appointment of Strategic Investor Relations Firm

MED is pleased to announce the appointment of Fairfax Partners Inc., a boutique investor relations firm, to enhance the Company's international communications and investor outreach. The firm will be supporting MED and its existing partners with tailored investor engagement and communications designed to enhance international visibility and ensure consistent, high-quality communication with the investment community as the Company advances its strategy of building a portfolio of 300+ MW. As part of this initiative, Fairfax will develop marketing materials including landing pages, investor presentations, and targeted outreach campaigns which fully articulate the current and future interests of MED.

 

 

Stay up to date with MED's latest news and updates by joining our emailing list and social media channels, as follows:

 

MED general enquiries - https://www.med.energy/contact

MED email alerts - https://www.med.energy/rnsannoucements-1

MED LinkedIn page - https://uk.linkedin.com/company/mast-energy-developments-plc

MED X (formerly Twitter) handle - @mastplc

 

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

Pieter Krügel

info@med.energy

Mast Energy

Developments PLC

CEO

Guy Wheatley, CFA

+44 (0)74 9398 9014

Fortified Securities

Corporate Broker

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBLFXEDLLBBB
Date   Source Headline
23rd Oct 20237:00 amRNSMED Binding JVA Completion Update
12th Oct 20232:03 pmRNSHolding(s) in Company
12th Oct 20232:01 pmRNSHolding(s) in Company
12th Oct 20232:00 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSIssue of Equity
22nd Sep 20237:00 amRNSMED Binding JVA Completion Update
1st Sep 20237:00 amRNSMED Binding Joint Venture Completion Update
25th Aug 20237:00 amRNSHalf-year Report
9th Aug 20232:16 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSMED Binding Joint Venture Completion Update
12th Jul 20231:15 pmRNSJoint Venture
6th Jun 20231:09 pmRNSResult of AGM
23rd May 20232:30 pmRNSIssue of Equity
22nd May 20233:00 pmRNSShares issue
18th May 20237:00 amRNSJV & Investment. New Broker & Loan Reprofiling
16th May 20231:15 pmRNSNotice of AGM
4th May 20237:00 amRNSQ1 Corporate Presentation and Website Update
28th Apr 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSPyebridge Update
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20222:05 pmRNSSecond Price Monitoring Extn
20th Dec 20222:00 pmRNSPrice Monitoring Extension
16th Dec 20227:00 amRNSPyebridge SPA Deferred Consideration Settlement
15th Dec 20222:00 pmRNSTR-1: Notification of major holdings
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
8th Dec 20227:00 amRNSBordesley Update
17th Nov 20227:00 amRNSCorporate Presentation
3rd Nov 20227:00 amRNSFurther Funding Secured
31st Oct 20221:41 pmRNSClarification of Pyebridge Trading Update
27th Oct 20224:41 pmRNSSecond Price Monitoring Extn
27th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Oct 20222:05 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
24th Oct 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20222:05 pmRNSSecond Price Monitoring Extn
24th Oct 20222:00 pmRNSPrice Monitoring Extension
24th Oct 202211:05 amRNSSecond Price Monitoring Extn
24th Oct 202211:00 amRNSPrice Monitoring Extension
24th Oct 20229:05 amRNSSecond Price Monitoring Extn
24th Oct 20229:00 amRNSPrice Monitoring Extension
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
21st Oct 20222:06 pmRNSSecond Price Monitoring Extn
21st Oct 20222:00 pmRNSPrice Monitoring Extension
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
20th Oct 20224:41 pmRNSSecond Price Monitoring Extn
20th Oct 20224:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.